

Few Novel drugs approved by USFDA in 2015

K Parushuram Naik¹, V Sai lakshmi², Jyothirmai³

^{1,2}Assistant Professor,³Professor, Department of Pharmacology, Prathima Institute of Medical Sciences, Nagunur, Karimnagar, Telangana, India

Address for correspondence: Dr. K.Parushuram Naik, Assistant Professor, Department of Pharmacology, Prathima Institute of Medical Sciences, Nagunur, Karimnagar, Telangana, India

Email: kprnaik2k10@gmail.com

Sl. No.	Drug Name	Active Ingredient	Indication	Dose	Route of admini
1	Zurampic.	Lesinurad ¹ .	High blood uric acid with gout.	200mg OD.	Oral.
2	Uptravi.	Selexipag ² .	Pulmonary arterial hypertension.	200mcg twice daily at weekly intervals max. Upto 1600mcg.	Oral.
3	Bridion.	Sugammadex ³ .	Reverse effects of neuromuscular blocking drugs used during surgery.	4mg/kg for spontaneous recovery, then 2mg/kg.	Intravenous use.
4	Nucala.	Mepolizumab ⁴ .	Add on drug for maintenance treatment of asthma.	100mg once every four weeks.	Subcutaneous inj.
5	Veltassa.	Patiromer ⁵ .	Serious hyperkalemia with high potassium levels	8.4gm OD with food.	Oral suspension.
6	Praxbind.	Idarucizumab ⁶ .	To reverse anticoagulant effect (blood thinning) of Dabigatran during emergency situations.	5gms.	Intravenous inj.
7	Kengreal.	Canegrelor ⁷ .	To prevent blood clots in coronary arteries during percutaneous coronary intervention.	30micrograms/ kg I.V. bolus prior to PCI, followed by 4 micrograms/ kg/min IV infusion for 2 hours.	Intravenous inj.
8	Tresiba.	Insulin degludec inj ⁸ .	Improve blood glucose control in DM patient's.	Depends on the blood glucose levels.	Subcutaneous
9	Repatha.	Evolocumab ⁹ .	To treat high cholesterol.	140 mg once every 2 week's or 420 mg once a month.	Subcutaneous inj. In abdomen, thighs.
10	Praluent.	Alirocumab ¹⁰ .	To treat high cholesterol.	75mg once every 2weeks.	Subcutaneous inj.
11	Entresto.	Sacubitril / Valsartan ¹¹ .	To treat heart failure.	Recommended starting dose 49/51 mg (S/V).	Oral

12	Corlanor.	Ivabradine ¹² .	To reduce hospitalization from worsening heart failure.	5 mg BD.	Oral.
13	Viberzi.	Eluxadoline ¹³ .	To treat inflammatory bowel syndrome with diarrhea.	100mg BD with food.	Oral.
14	Orkambi.	Lumacaftor 200mg/ Ivacaftor 125mg ¹⁴ .	To treat cystic fibrosis.	2 tablets every 12 hourly	Oral.
15	Cosentyx	Secukinumab ¹⁵ .	To treat moderate to severe plaque psoriasis.	300 mg at weeks 0,1,2,3,&4 then 300 mg every 4weeks. 150 mg loading dose at weeks 0,1,2,3,&4 followed by 150 mg every 4weeks. Same as above.	Subcutaneous inj.
16	Aristada.	Aripiprazole ¹⁶ .	To treat schizophrenia.	441 mg	Intramuscular inj.
17	Vraylar.	Cariprazine ¹⁷ .	To treat schizophrenia and bipolar disorder.	1.5 to 6 mg/	
18	Rexulti..	Brexpiprazole ¹⁸ .	To treat schizophrenia and add on to an antidepressant to treat major depressive disorder	. 1-2mg/day.	Oral.

REFERENCES

1. <https://www.astrazeneca.com/media-centre/press-releases/2015/ZURAMPIC-lesinurad-approved-by-US-FDA-for-patients-with-gout-22122015.html>.
2. <http://www1.actelion.com/en/our-company/news-and-events.page?newsId=1975263>.
3. <http://www.mercknewsroom.com/news-release/corporate-news/mercks-bridion-sugammadex-receives-fda-approval-reversal-neuromuscular>.
4. <https://www.gsk.com/en-gb/media/press-releases/2015/gsk-s-nucala-mepolizumab-receives-approval-from-us-fda/>.
5. <http://www.relypsa.com/our-medicine/veltassa/>.
6. http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2015/10-16-2015-fda-approves-praxbind-idarucizumab-specific-reversal-agent-pradaxa-dabigatran-etexilate-mesylate.html.
7. <http://www.drugs.com/history/kengreal.html>.
8. <http://www.novo-pi.com/tresiba.pdf>
9. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125522s000lbl.pdf
10. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000bledt.pdf
11. <http://entresto.com/>.
12. <https://www.corlanorhpc.com/>.
13. <http://www.actavis.com/NEWS/News/Thomson-Reuters/Actavis-Receives-FDA-Approval-for-VIBERZI-eluxadol>.
14. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf
15. <http://www.pharma.us.novartis.com/product/pi/pdf/cosentyx.pdf>
16. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf
17. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf
18. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422s000lbl.pdf

Please cite this article as: Naik, Sailakshmi, Jyothirmai. Few Novel drugs approved by USFDA in 2015. Perspectives in medical research 2016;4:1:67-68.

Sources of Support: Nil, Conflict of interest: None declared